FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Journal: Nature Immunology

Published: 2020-05-04

DOI: 10.1038/s41590-020-0669-6

Affiliations: 12

Authors: 18

Go to article
Institutions Share
Program in Cellular and Molecular Medicine (PCMM), BCH, United States of America (USA) 0.28
Harvard Department of Biological Chemistry and Molecular Pharmacology (BCMP), United States of America (USA) 0.20
CAS Key Laboratory of Molecular Virology and Immunology, IPS-CAS, China 0.19
Harvard Department of Pediatrics, United States of America (USA) 0.10
Biomolecular Resource Facility, UTMB, United States of America (USA) 0.06
Department of Laboratory Medicine, BCH, United States of America (USA) 0.03
Stem Cell Program, BCH, United States of America (USA) 0.03
Harvard Department of Pathology, United States of America (USA) 0.03
Harvard Dana-Farber/Harvard Cancer Center (DF/HCC), United States of America (USA) 0.03
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.03
Beijing Hospital of TCM, Capital Medical University, China 0.02
Department of Immunology, UConn, United States of America (USA) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER